Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-5.36% $1.060
America/New_York / 28 jun 2021 @ 00:00
FUNDAMENTALS | |
---|---|
MarketCap: | 11.15 mill |
EPS: | 0 |
P/E: | 0 |
Earnings Date: | N/A |
SharesOutstanding: | 10.52 mill |
Avg Daily Volume: | 0.141 mill |
RATING 2022-02-09 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
1/19 | 2/19 | 1/20 | 2/20 | 1/21 | 2/21 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | n/a | n/a | n/a | |||
Asset | n/a | n/a | n/a | |||
Debt | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 0 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
N/A |
Company: PE 0 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.966 - 1.154 ( +/- 8.87%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2020-06-22 | Nuechterlein Carole | Buy | 12 000 | Stock Option (right to buy) |
2020-06-22 | Howe John P Md | Buy | 12 000 | Stock Option (right to buy) |
2020-06-22 | Gallagher Carol Giltner | Buy | 12 000 | Stock Option (right to buy) |
2020-06-22 | Nichol Geoffrey | Buy | 12 000 | Stock Option (right to buy) |
2020-06-22 | Hindman James M. | Buy | 12 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
0.00 |
Last 34 transactions |
Buy: 816 539 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $1.060 (-5.36% ) |
Volume | 1.913 mill |
Avg. Vol. | 0.141 mill |
% of Avg. Vol | 1 356.71 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.